NLRP3 and hydrops fetalis: TFEB activators, TRPML1 agonists, and NLRP3 inflammasome inhibitors are among the promising candidates that may help stabilize lysosomal homeostasis and alleviate metabolic and inflammatory stress in patients with HF [72,77].